blood analyzer News
-
Sight Diagnostics in The New York Times] Israel’s Sight Diagnostics Raises $71 Million for Its Blood Analyzer
Israel’s Sight Diagnostics said on Wednesday it raised $71 million in private funding to expand sales of its finger-prick blood analyzer and support research and development. Koch Disruptive Technologies, Longliv Ventures, which is part of the CK Hutchison Group, and Israel’s OurCrowd participated in the round, which brings Sight’s total funding to more than $124 million. Read ...
-
Israeli blood test startup Sight Diagnostics inks deal for distribution in UAE
Israel’s Sight Diagnostics, a startup that analyzes blood samples with a small device in minutes, has inked a deal to install its products in the United Arab Emirates and other Gulf countries. The company said on Wednesday it had agreed to a distribution partnership with the Dubai-based business development firm Phoenix Capital. Sight will provide its OLO blood analyzer machines to nine ...
-
Chronus Health Raises Series A Financing
Company poised to disrupt $80 billion U.S. clinical laboratory market Chronus Health, a point-of-care diagnostics company, announced today that it has raised $22 million Series A financing led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor. While several on-site blood analyzers are already available in the ...
-
Daxor corporation announces novel fluorescent tracer and phasetwo us air force contract award of $750,000 for point-of-care Optical blood volume analyzer
Daxor Corpora9on (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two contract from the United States Air Force (USAF) to implement a novel fluorescent tracer and op9cal sensing technology into a next-genera9on point-of-care blood volume analyzer. This is the fourth contract award Daxor has received from the Department of ...
-
OPTI Medical Systems Launches the E-Lyte CCA Cassette
OPTI Medical is pleased to announce the launch of our E-Lyte CCA cassette for use on the OPTI CCA-TS and TS2 Blood Gas and Electrolyte Analyzers. With measured pH, Na+, K+, Ca++, Cl- and calculated tCO2 and HCO3-, the E-Lyte CCA test configuration is designed to assist in the detection of renal failure. For a complete list of features, to request a sample or to schedule a ...
-
Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2022. The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100 Blood Volume Analyzer through a ...
-
Nova Blood Gas Analyzers Add Important New Test: Mean Corpuscular Hemoglobin Concentration (MCHC)
Waltham, MA - Nova Biomedical announces the addition of another important critical care parameter to its Stat Profile Prime Plus blood gas analyzer—the ability to rapidly calculate and report mean corpuscular hemoglobin concentration (MCHC). MCHC is a measure of the hemoglobin concentration in a given volume of packed red blood cells. MCHC, along with measured hemoglobin and ...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress ...
-
Daxor’s Blood Volume Analyzer (BVA-100) to Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology. The study is ...
-
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announced Launch Tennessee (LaunchTN) has awarded Daxor Corporation a SBIR/STTR matching fund grant for Daxor’s Phase II award from the Department of Defense in the amount of $200K for the development of its next-generation point-of-care blood volume analyzer. “Receiving this grant is a ...
-
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol ...
-
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL. Mr. Feldschuh will present on May 25, 2022 at 4:30pm ET and will report on the many ...
-
RURAL Cohort Study to Utilize PixCell Medical`s HemoScreen Hematology Analyzer for Research Initiative
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell's novel miniaturized, portable hematology analyzer, HemoScreen™, as part of its six year research study, aiming to gain insight into the specific health-related concerns of the rural southeastern United States' ...
-
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will present at Maxim Group 2022 Virtual Growth Conference to be held March 28-30, 2022, 9:00 AM – 5:30 PM ET. The conference will feature a company presentation, fireside chats, roundtable discussions, and live Q&A with Mr. Feldschuh moderated ...
-
Sight Diagnostics raises $71 million amidst Covid-19 demand for blood count devices
Israeli blood testing startup S.D. Sight Diagnostics Ltd. has raised $71 million from international venture capital funds and U.S. corporations, Clal Biotechnology Industries Ltd. revealed in a report sent to the Tel Aviv Stock Exchange last week. Sight Diagnostics has yet to announce the details of the new funding round, but Clal Biotechnology Industries stated in its report that following the ...
-
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022. “The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on ...
-
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways. “We are very excited ...
-
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to ...
-
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you